With an annual budget of more than 20 M€, CARIM is one of the largest cardiovascular research institutes in Europe, producing more than 500 scientific articles and approximately 40 PhD dissertations per year. In the last ten years, CARIM papers were published in high impact journals such as Cell, JAMA, Nature Medicine, New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, and Lancet Neurology.
CARIM offers a very broad range of facilities covering the entire field of translational cardiovascular research and many internship opportunities, taking advantage of its connection with a large academic hospital. CARIM has an open and dynamic work culture in which talented and ambitious young people work side by side with renowned researchers and medical specialists. CARIM is an active research institute that enables its employees and provides support, such as assistance with applications for research grants and funding, a talent development programme and a Research Council, that reviews project proposals before they are submitted. CARIM provides a dynamic, critical learning environment, which proves to be fertile ground for top achievements in the field of cardiovascular research.
CARIM is one of the six schools of the Faculty of Health, Medicine and Life Sciences (FHML) of Maastricht University and is embedded within the Maastricht University Medical Center+ (Maastricht UMC+). CARIM collaborates closely with the Heart+Vascular Center of Maastricht UMC+.
• 21.5 M€ annual budget
• annually > 650 publications in Science Citation indexed journals
• 233 researchers, including 98 PhD students
• 67 support staff
• 17 clinical and basic research departments
• Led by Prof. Tilman Hackeng
The Maastricht Study
CARIM is one of the initiators of the Maastricht Study; a large, longitudinal population based cohort study focused on type 2 diabetes, and its related co-morbidities. The study will include and track 10,000 individuals living in the Southern part of the Netherlands over a ten-year period. Participants are 40 to 75 years old, and half of them will have type 2 diabetes.
More information >
The Maastricht Heart+Vascular Center (HVC)
Part of the Maastricht UMC+. At HVC, not only are cardiovascular disease treated, but specific advice on lifestyle, weight and diet to prevent cardiovascular disease is given. HVC holds an international top ranking position on Aortic disease, Thrombosis, Arrhythmias and Heart Failure.
More information >
Aachen-Maastricht Institute for CardioRenal Disease (AMICARE)
Pioneering into the field of cardiorenal research, the RWTH Aachen and Maastricht University have established a strong and successful cross-border collaboration over the past 10 years, bringing cardiovascular and renal research of both institutes closely together. AMICARE, as a joint international institute between the RWTH Aachen and Maastricht University, brings the cooperation between Aachen and Maastricht in the field of cardiorenal research to the highest level: The full potential in the development of innovative diagnostic and therapeutic approaches, international visibility as well as industry-relevant research is being exploited.
AMICARE is located in Germany on the RWTH Aachen Campus. In AMICARE, researchers and clinicians work intensively together with private partners, including pharmaceutical companies, biotech and medical device companies. Such direct and interdisciplinary interaction of basic researchers, clinicians and private partners in AMICARE offers exactly what is needed to increase research translation, valorisation and exploitation.
More information >